FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1811441310> ?p ?o ?g. }

• W1811441310 endingPage "305" @default.
• W1811441310 startingPage "299" @default.
• W1811441310 abstract "The urokinase plasminogen activator (uPA) system is involved in tissue remodelling processes and is up-regulated in many types of malignancies. We investigated whether serum levels of different forms of soluble uPA receptor (suPAR) are associated with survival and in particular with prostate cancer and cardiovascular disease mortality.Using time-resolved fluorescence immunoassays, we measured intact suPAR [suPAR(I-III)] and intact plus cleaved suPAR [suPAR(I-III) + suPAR(II-III)] and thus calculated the amount of suPAR(II-III) in serum samples from 375 men participating in a prostate cancer screening trial. A total of 312 men were free of prostate cancer and 63 men had prostate cancer diagnosed at the time of screening. The cohort was followed for 15 years. We assessed survival using Kaplan-Meier estimation and Cox proportional hazards regression.The mean age at blood sampling was 64 years. In total, 152 men died during follow-up. SuPAR(I-III) and suPAR(II-III) were significantly positively associated with mortality (P = 0.001 and P < 0.0001, respectively). In a Cox regression model adjusting for age and prostate cancer status, an increase in suPAR(I-III) and suPAR(II-III) by 1-unit (ln-scale) was associated with a hazard ratio (HR) of 2.26 [95% confidence interval (CI) 1.17-4.35] and 2.53 (95% CI 1.56-4.10), respectively. There was a trend towards an increased risk of death from prostate cancer in screening-detected prostate cancer patients with increased values of either suPAR form. However, this difference was not significant and the association disappeared after adjusting for age, tumour stage, tumour grade and prostate-specific antigen. Being in the highest quartile of any of the suPAR forms was associated with a highly significant increased risk of cardiovascular death, with HR adjusted for age of 3.27 (95% CI 1.38-7.73) for suPAR(I-III) quartile 4 versus quartile 1. Conclusions. High concentrations of serum suPAR(I-III) and suPAR(II-III) were associated with poor overall survival. The association was particularly strong for death from cardiovascular disease. No similar association was found for prostate cancer after adjustment for other prognostic factors." @default.
• W1811441310 created "2016-06-24" @default.
• W1811441310 creator A5015559656 @default.
• W1811441310 creator A5024216962 @default.
• W1811441310 creator A5030700064 @default.
• W1811441310 creator A5051406597 @default.
• W1811441310 creator A5052385412 @default.
• W1811441310 creator A5056770711 @default.
• W1811441310 creator A5080395405 @default.
• W1811441310 creator A5083589922 @default.
• W1811441310 date "2010-12-08" @default.
• W1811441310 modified "2023-10-18" @default.
• W1811441310 title "Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening" @default.
• W1811441310 cites W1569704448 @default.
• W1811441310 cites W1869177682 @default.
• W1811441310 cites W1933982817 @default.
• W1811441310 cites W1973343326 @default.
• W1811441310 cites W1978031623 @default.
• W1811441310 cites W1990646545 @default.
• W1811441310 cites W1991104802 @default.
• W1811441310 cites W1996030902 @default.
• W1811441310 cites W1997506248 @default.
• W1811441310 cites W2010695917 @default.
• W1811441310 cites W2044750449 @default.
• W1811441310 cites W2048853385 @default.
• W1811441310 cites W2050181619 @default.
• W1811441310 cites W2061016962 @default.
• W1811441310 cites W2063019110 @default.
• W1811441310 cites W2086711080 @default.
• W1811441310 cites W2093019243 @default.
• W1811441310 cites W2094720609 @default.
• W1811441310 cites W2101353737 @default.
• W1811441310 cites W2109030321 @default.
• W1811441310 cites W2109850844 @default.
• W1811441310 cites W2123579958 @default.
• W1811441310 cites W2126149673 @default.
• W1811441310 cites W2129452239 @default.
• W1811441310 cites W2141761576 @default.
• W1811441310 cites W2143624574 @default.
• W1811441310 cites W2412055773 @default.
• W1811441310 cites W2413852552 @default.
• W1811441310 cites W4255839779 @default.
• W1811441310 doi "https://doi.org/10.1111/j.1365-2796.2010.02284.x" @default.
• W1811441310 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21138491" @default.
• W1811441310 hasPublicationYear "2010" @default.
• W1811441310 type Work @default.
• W1811441310 sameAs 1811441310 @default.
• W1811441310 citedByCount "30" @default.
• W1811441310 countsByYear W18114413102012 @default.
• W1811441310 countsByYear W18114413102013 @default.
• W1811441310 countsByYear W18114413102014 @default.
• W1811441310 countsByYear W18114413102015 @default.
• W1811441310 countsByYear W18114413102016 @default.
• W1811441310 countsByYear W18114413102017 @default.
• W1811441310 countsByYear W18114413102018 @default.
• W1811441310 countsByYear W18114413102019 @default.
• W1811441310 countsByYear W18114413102020 @default.
• W1811441310 countsByYear W18114413102021 @default.
• W1811441310 crossrefType "journal-article" @default.
• W1811441310 hasAuthorship W1811441310A5015559656 @default.
• W1811441310 hasAuthorship W1811441310A5024216962 @default.
• W1811441310 hasAuthorship W1811441310A5030700064 @default.
• W1811441310 hasAuthorship W1811441310A5051406597 @default.
• W1811441310 hasAuthorship W1811441310A5052385412 @default.
• W1811441310 hasAuthorship W1811441310A5056770711 @default.
• W1811441310 hasAuthorship W1811441310A5080395405 @default.
• W1811441310 hasAuthorship W1811441310A5083589922 @default.
• W1811441310 hasBestOaLocation W18114413101 @default.
• W1811441310 hasConcept C121608353 @default.
• W1811441310 hasConcept C126322002 @default.
• W1811441310 hasConcept C126894567 @default.
• W1811441310 hasConcept C143998085 @default.
• W1811441310 hasConcept C207103383 @default.
• W1811441310 hasConcept C2776235491 @default.
• W1811441310 hasConcept C2776892390 @default.
• W1811441310 hasConcept C2776929539 @default.
• W1811441310 hasConcept C2780192828 @default.
• W1811441310 hasConcept C29456083 @default.
• W1811441310 hasConcept C44249647 @default.
• W1811441310 hasConcept C50382708 @default.
• W1811441310 hasConcept C56219504 @default.
• W1811441310 hasConcept C71924100 @default.
• W1811441310 hasConcept C90924648 @default.
• W1811441310 hasConceptScore W1811441310C121608353 @default.
• W1811441310 hasConceptScore W1811441310C126322002 @default.
• W1811441310 hasConceptScore W1811441310C126894567 @default.
• W1811441310 hasConceptScore W1811441310C143998085 @default.
• W1811441310 hasConceptScore W1811441310C207103383 @default.
• W1811441310 hasConceptScore W1811441310C2776235491 @default.
• W1811441310 hasConceptScore W1811441310C2776892390 @default.
• W1811441310 hasConceptScore W1811441310C2776929539 @default.
• W1811441310 hasConceptScore W1811441310C2780192828 @default.
• W1811441310 hasConceptScore W1811441310C29456083 @default.
• W1811441310 hasConceptScore W1811441310C44249647 @default.
• W1811441310 hasConceptScore W1811441310C50382708 @default.
• W1811441310 hasConceptScore W1811441310C56219504 @default.
• W1811441310 hasConceptScore W1811441310C71924100 @default.
• W1811441310 hasConceptScore W1811441310C90924648 @default.

• next